A new approach to treat Alzheimer’s disease

Alzheimer; News from the web:

A new approach to treat Alzheimer’s disease, potentially targeting the root cause of memory decline

The ACT-AD and LIFT-AD trials are evaluating if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease.

The investigational drug of the ACT-AD and LIFT-AD trials is designed to:

  • Boost a repair and regenerative pathway for brain cells
  • Promote brain health and function

There may be a trial near you check it out

Read all about it HERE

A safer Alzheimer’s drug

Alzheimer; News from the web:

In 2018, a research group led by David Holtzman, M.D., at Washington University in St. Louis developed an antibody drug in collaboration with Denali Therapeutics that showed promise as a potential Alzheimer’s disease therapy. Now, the team has returned with mouse data suggesting the drug prospect might be a safer option than Biogen’s much-hyped aducanumab.

Read all about it HERE

A Vaccine for Alzheimer’s Disease?

Alzheimer; News from the web:

Swiss biopharma AC Immune has made targeting Alzheimer’s disease, the leading form of dementia, a top priority. The company’s numerous candidates and platforms target several different proteins and pathways thought to have a central role in Alzheimer’s pathology. 2020 has brought mixed news for AC Immune. In July, the company announced that their candidate tau vaccine, ACI-35.030, had shown “encouraging” safety data at a lower dose and was to be progressed to a higher-dose group. However, September brought the disappointing news that their anti-tau antibody, semorinemab, did not meet its primary efficacy endpoints in a Phase 2 trial. To discuss AC Immune’s work, Technology Networks spoke to CEO Prof. Andrea Pfeifer.

https://www.technologynetworks.com/

Read all about it HERE

FDA does not approve new Alzheimer’s drug

Alzheimer; News from the web:

Government health advisers sharply criticized a closely watched Alzheimer’s drug on Friday, concluding there wasn’t enough evidence that the experimental drug slowed the brain-destroying disease.

The panel of outside experts for the Food and Drug Administration agreed that a pivotal study in patients failed to show “strong evidence” that the drug worked. The experts warned of multiple “red flags” with the data, which did not initially show any benefit until another analysis with later results.

Read all about it HERE

Get your flu shot, avoid Alzheimer’s

Alzheimer; News from the web:

Everyone has their eyes on this year’s flu season, which is predicted to collide with the on-going COVID-19 pandemic.

The CDC and other health agencies are already issuing strong recommendations to the public to get their flu shot as early as possible.

In addition to protecting against the flu, flu shots may also have an unexpected benefit: lowering the risk of Alzheimer’s disease.

Read all about it HERE

A better test for Alzheimer’s

Alzheimer; News from the web:

Clinical trials of Alzheimer’s medicines have failed frequently but now researchers believe that this may have been caused by the drugs given too late. So if they could just develop a test that would detect Alzheimer’s earlier, it would make the drugs that have failed for use later in the process, so much more productive.

Read all about it HERE

Alzheimer surprise drug

Alzheimer; News from the web:

Despite many promising leads, more than 120 drug treatments for Alzheimer’s disease have failed. But Cambridge-based biotech company Biogen revived hope on Tuesday with its announcement that it would seek Food and Drug Administration approval for a drug it abandoned earlier this year.

Read all about it HERE

That new medicine for Alzheimer’s

Alzheimer; News from the web:

The biotech world went into a full-on frenzy Tuesday when drug giant Biogen dropped this whopper: The company is reviving its Alzheimer’s drug hopeful, aducanumab, after leaving it for dead all the way back in March. In fact, it’s marching forward with a Food and Drug Administration (FDA) application to approve the drug for certain patients facing cognitive decline.

Read all about it HERE

Status of Alzheimer’s research

Alzheimer; News from the web:

There are roughly 326 active, recruiting or enrolling by invitation clinical trials on the elusive disease, per clinicaltrial.gov. The U.S. last year dramatically stepped up funding for Alzheimer’s disease research, from $400 million a year to over $2 billion annually, although the Alzheimer’s Association says more is needed.

The biggest problem: Scientists still don’t know the cause of Alzheimer’s.

Read all about it HERE

Failed trial

Alzheimer; News from the web:

The companies developing aducanumab, Biogen and its partner Eisai, announced that they halted two late-stage trials of the experimental drug after an independent group’s analysis showed that the trials were unlikely to “meet their primary endpoint.”

The Cambridge, Massachusetts-based biotech giant joins a long list of companies in the last decade that have failed to find a treatment for Alzheimer’s.

Read all about it HERE

The end to senior moments near?

Alzheimer; News from the web:

A new drug shows promising results: Early results indicate that the drug could reverse natural, age-related cognitive decline. Researchers also believe that it might help patients whose memories are impaired because of conditions such as depression, schizophrenia and Alzheimer’s disease.

Read all about it HERE